Rezpegaldesleukin

Phase 3Protein / enzyme

Rezpegaldesleukin is one of 3 small molecule programs targeting Moderate to Severe Atopic Dermatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Moderate to Severe Atopic DermatitisActive, not recruiting

Moderate to Severe Atopic DermatitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Moderate to Severe Atopic Dermatitis

#DrugCompanyPhaseTrials

Rezzayo

Roche

Phase 2

2 2

Rezpegaldesleukin

NNektar Therapeutics

Phase 3

3 3

LW402

SShanghai Longwood Biopharmaceuticals Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Moderate to Severe Atopic Dermatitis

NCT06136741

Q2 2028

Phase 2Recruiting

Type 1 Diabetes Mellitus

NCT07142252

Q4 2028

Phase 3Recruiting

Moderate to Severe Atopic Dermatitis

NCT07690371

Q1 2029

Phase 3Recruiting

Moderate to Severe Atopic Dermatitis

NCT07711418

Clinical

Trials by Indication[1]

Moderate to Severe Atopic Dermatitis3 trials

A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

Recruiting·NNektar Therapeutics·Phase 3·NCT07690371·510 enrolled

Recruiting·NNektar Therapeutics·Phase 3·NCT07711418·510 enrolled

A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLVE-AD)

Active, not recruiting·NNektar Therapeutics·Phase 2·NCT06136741·396 enrolled

Alopecia Areata1 trial

A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

Completed·NNektar Therapeutics·Phase 2·NCT06340360·94 enrolled

Type 1 Diabetes Mellitus1 trial

Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus

Recruiting·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT07142252·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Rezpegaldesleukin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rezpegaldesleukin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rezpegaldesleukin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nektar Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: NNektar Therapeutics

Rezpegaldesleukin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2028

Q4 2028

Q1 2029

Trials by Indication[1]

Moderate to Severe Atopic Dermatitis3 trials

Alopecia Areata1 trial

Type 1 Diabetes Mellitus1 trial

References

Drug Info

Quick Facts

Related News